OOIR: Observatory of International Research

Papers

(The TQCC of Clinical and Molecular Hepatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	774
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	657
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver dise	572
Letter to the editor on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”	392
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	327
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	290
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement	267
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023	225
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	221
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	173
Preface	162
Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges	143
Navigating discordant non-invasive fibrosis assessments in metabolic dysfunction-associated steatotic liver disease: Implications for generalizability, clinical decision-making, and resource allocatio	138
Reply to correspondence on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	122
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	103
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	96
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	89
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	88
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”	81
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	79
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	78
HCC surveillance after curative treatment: A new frontier for abbreviated MRI: Editorial on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after cura	77
Clinical applications of immunogenomics in hepatocellular carcinoma	73
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	72
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	71

Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	69
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	69
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	69
2025 KASL clinical practice guidelines for management of hepatitis C	68
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	68
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	67
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	65
Toward hepatitis C virus elimination using artificial intelligence	64
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	64
Targeting ER lipid raft-associated 1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma	61
Liver organoids: Current advances and future applications for hepatology	60
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	60
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	59
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	59
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates	58
Rethinking lean metabolic dysfunction-associated steatotic liver disease: Unrecognized risk in lean populations: Editorial on “Normal-weight metabolic dysfunction-associated steatotic liver disease: R	58
Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-asso	57
Ethanol‑specific stress and RAB25/GCN1 signaling: Emerging perspectives in alcohol‑associated liver disease: Editorial on “RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol	56
Correspondence to editorial on “MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD”	56
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	55
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	55
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	54
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	53
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	52
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	52
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients wi	50
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	47
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	46
Correspondence to letter to the editor on “Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparis	46
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	44
Reply to correspondence on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disea	43
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	43
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	41
What is new in the 2024 Chinese guidelines for fatty liver disease?	40
A decade of liver organoids: Advances in disease modeling	40
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	39
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	37
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	37
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	37
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver d	36
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	36
Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy	36
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	36
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	36
Abnormal Lipid Status Attenuates the Protective Association of Vitamin E With Pediatric MASLD	35
Clinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoring	35
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	35
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	34
Steatotic Liver Disease: Non-Invasive Assessment and Biomarkers Across MASLD, MetALD and ALD	34
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	33

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	33
From post-transplant outcomes to listing decisions: Clinical implications of comparing expanded hepatocellular carcinoma transplant criteria: Letter to the editor on “Network meta-analysis and validat	33
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	32
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	32
Plasma lipidomic and fungal signatures predict early mortality in acute liver failure	32
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	32
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	32
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	31
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	30
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	30
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	30
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	30
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogue	30
Precision chemotherapy in biliary tract cancer moving from empiric intensification to biomarker-guided treatment: Editorial on “Molecular determinants of outcome to gemcitabine, cisplatin, and nab-pac	29
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	29
Discordant FIB-4 and liver stiffness in metabolic dysfunction-associated steatotic liver disease as related to histology and liver-related events in a global cohort: Editorial on “Histological severit	29
Rethinking ACLF prognosis: Can machine learning outperform conventional scores?: Editorial on “Predictive machine learning model in intensive care unit patients with acute-on-chronic liver failure and	29
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	29
Immunopathogenesis of liver fibrosis in steatotic liver disease	28
Berberine and the gut microbiota - A novel treatment strategy for cholestatic liver disease: Editorial on “Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppres	28
Global incidence and prevalence of nonalcoholic fatty liver disease	28
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	27
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	27
Interaction between sarcopenia and nonalcoholic fatty liver disease	27
Acute-on-chronic liver failure: Terminology, mechanisms and management	27
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	27
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma	27
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	26
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	26
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	26
A new Korean nomenclature for steatotic liver disease	26
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	26
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and no	25
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	25
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”	25
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	25
Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma	24
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	24
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation	24
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	24
A cost-effectiveness evaluation framework for treatment for metabolic dysfunction-associated steatohepatitis: Potential and concerns: Editorial on “Evaluating treatment response thresholds for cost-ef	24
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	24
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	23
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	23
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	23
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	22
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	22
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	22
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	21
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	21
Screening strategy for non-alcoholic fatty liver disease	21
Regulation of hepatitis B virus cccDNA by metabolic pathways: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”	21
Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches	21
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	21
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	21
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis	20
Reply to correspondence on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”	20
KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026	20
Correspondence to letter to the editor on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	20
Depression and suicide-related events associated with tenofovir use in chronic hepatitis B: A pharmacovigilance analysis	20
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	20
DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα	20
Clarifying residual drug effects and subgroup outcomes in TDF-to-BSV switch trials: Letter to the editor on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil	20
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	19
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	19
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	19
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	19
Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”	18
Clinical implications of residual changes following HCV clearance: Editorial on “Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy”	18
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	18
PRMT1-mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression	18
Rising burden of alcohol-associated liver disease and cancers: Insights into sex disparities and policy implications: Editorial on “Sex disparities in alcohol-associated liver disease and subtype diff	18
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	18
JCAD, a new potential therapeutic target in cholestatic liver disease	17
The magic of sodium-glucose cotransporter-2 inhibitors: Benefits in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: Editorial on “Comparative risk of fibrosis pr	17
ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling	17
Evidence-based hyponatremia management in liver disease	17
vibraA non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: The Baveno VI-SSM combined model: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related e	17
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	16
Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study	16

Clinical implications of discordant FIB-4 and LSM in MASLD: Integrating evidence and optimizing pathways: Letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic	16
Challenges and innovations in MASLD and T2DM: Strengthening personalized medicine with SGLT2 inhibitors: Editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs.	16
Harmonized ACLF prognostication with explainable machine learning models: Traversing from counts to composition: Editorial on “Predictive machine learning model in intensive care unit patients with ac	16
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	15
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	15
Extending MET-TRIB3 axis research in hepatocellular carcinoma: Immune contexture and patient subgroups: Letter to the editor on “MET promotes hepatocellular carcinoma development through the promotion	15
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	15
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	15
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	15
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	14
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	14
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	14
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	14
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	14
Management of refractory ascites	14
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	14
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	13
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	13
Roles of X-box binding protein 1 in liver pathogenesis	13
Non-alcoholic fatty liver disease: Definition and subtypes	13
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	13
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	13
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	13
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	13
Plasma exchange and abrogation of monocyte activation in Wilson’s disease: Letter to the editor on “Acute-on-chronic liver failure: Terminology, mechanisms and management”	13
COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling	13
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	12
Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure	12
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	12
Risk Assessment of Cardiovascular Disease-related Mortality in Metabolic Dysfunction-Associated Steatotic Liver Disease	12
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	11
Congratulatory remarks	11
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	11
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	11
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	11
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	11
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study”	11
Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness	11
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	11
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic	11
Acute hepatitis C virus infection: clinical update and remaining challenges	11
A call for more efforts to incorporate liver in the metabolic health framework: Letter to the editor on “Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-asso	11
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	10
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	10
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	10
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	10
Hepatorenal syndrome: Current concepts and future perspectives	10
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	10
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	10
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	9
Letter to the editor 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes melli	9
The latest global burden of liver cancer: A past and present threat	9
Correspondence to Editorial 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Letter to the editor on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver dise	9
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features	9
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen	9
Burden of cardiovascular complications in steatotic liver disease in the United States	9
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	9
Targeting the innate immune system in treating hepatitis B: prospects for functional cure	9
Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings	9